Search

Your search keyword '"Alvegard, Thor A."' showing total 18 results
Start Over Author "Alvegard, Thor A."
18 results on '"Alvegard, Thor A."'

3. Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.

Author

Joensuu, Heikki, primary, Eriksson, Mikael, additional, Sundby Hall, Kirsten, additional, Reichardt, Annette, additional, Hermes, Barbara, additional, Schuette, Jochen, additional, Cameron, Silke, additional, Hohenberger, Peter, additional, Jost, Philipp, additional, Al-Batran, Salah-Eddin, additional, Lindner, Lars H, additional, Bauer, Sebastian, additional, Wardelmann, Eva, additional, Nilsson, Bengt E., additional, Kallio, Raija S., additional, Jaakkola, Panu, additional, Junnila, Jouni, additional, Alvegard, Thor, additional, and Reichardt, Peter, additional

Published
2020
Full Text
View/download PDF

4. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups

Author

Ferrari, Stefano, Smeland, Sigbjorn, Mercuri, Mario, Bertoni, Franco, Longhi, Alessandra, Ruggieri, Pietro, Alvegard, Thor A., Picci, Piero, Capanna, Rodolfo, Bernini, Gabriella, Müller, Cristoph, Tienghi, Amelia, Wiebe, Thomas, Comandone, Alessandro, Böhling, Tom, Del Prever, Adalberto Brach, Brosjö, Otte, Bacci, Gaetano, and Sæter, Gunnar

Published
2005
Full Text
View/download PDF

7. Malignant fibrous histiocytoma of soft tissue: a population-based epidemiologic and prognostic study of 137 patients

Author

Rooser, Bo, Willen, Helena, Gustafson, Pelle, Alvegard, Thor A., and Rydholm, Anders

Subjects
Dermatofibroma -- Demographic aspects, Dermatofibroma -- Prognosis, Health
Abstract

Despite the fact that malignant fibrous histiocytoma was only first described as a class of tumor in the early 1960s, these cancers are the most common sarcomas of soft tissue. There have been relatively few research papers published that are devoted exclusively to these cancers. Also, some of the findings of these studies are inconsistent, which may be attributed to selection bias. Since often only the larger and more serious histiocytomas are referred to major medical centers, tabulations of data on these tumors by these medical centers are not representative of the full range of the cancers that actually occur. To provide an insight into the spectrum malignant fibrous histiocytomas as they occur in the population, a population-based study of 137 patients was conducted. While the average age was 64 years, the cancer occurred in patients as young as 22 years. The annual incidence of malignant fibrous histiocytoma was 0.42 cases per 100,000 people per year. Malignant fibrous histiocytoma occurs in a variety of histologic types, and the type plays an important role in predicting survival. The majority of such cancers have a mixture of pleomorphic (many shapes) and storiform (a matted, irregular pattern) histologic types. In the present study, 83 patients had storiform or pleomorphic tumors. These types are highly malignant with a chance of metastatic disease of about 50 percent. The five-year survival rate for the storiform-pleomorphic histiocytoma was 0.5, and was strongly associated with metastasis. In contrast, the five-year survival rate for the 53 patients with the myxoid histologic type was a perfect 1.0. While some previous studies found an association between survival and locoregional recurrence, the development of local recurrence did not influence survival in this study. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

8. The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma

Author

Trovik, Clement, Bauer, Henrik C. F., Styring, Emelie, Sundby Hall, Kirsten, Vult von Steyern, Fredrik, Eriksson, Sigvard, Johansson, Ingela, Sampo, Mika, Laitinen, Minna, Kalén, Anders, Jonsson, Halldor Jr., Jebsen, Nina, Eriksson, Mikael, Tukiainen, Erkki, Wall, Najme, Zaikova, Olga, Sigurdsson, Helgi, Lehtinen, Tuula, Bjerkehagen, Bodil, Skorpil, Mikael, Egil Eide, Geir, Johansson, Elisabeth, Alvegard, Thor A., Trovik, Clement, Bauer, Henrik C. F., Styring, Emelie, Sundby Hall, Kirsten, Vult von Steyern, Fredrik, Eriksson, Sigvard, Johansson, Ingela, Sampo, Mika, Laitinen, Minna, Kalén, Anders, Jonsson, Halldor Jr., Jebsen, Nina, Eriksson, Mikael, Tukiainen, Erkki, Wall, Najme, Zaikova, Olga, Sigurdsson, Helgi, Lehtinen, Tuula, Bjerkehagen, Bodil, Skorpil, Mikael, Egil Eide, Geir, Johansson, Elisabeth, and Alvegard, Thor A.

Abstract

Purpose - We wanted to examine the potential of the Scandinavian Sarcoma Group (SSG) Central Register, and evaluate referral and treatment practice for soft-tissue sarcomas in the extremities and trunk wall (STS) in the Nordic countries. Background - Based on incidence rates from the literature, 8,150 (7,000-9,300) cases of STS of the extremity and trunk wall should have been diagnosed in Norway, Finland, Iceland, and Sweden from 1987 through 2011. The SSG Register has 6,027 cases registered from this period, with 5,837 having complete registration of key variables. 10 centers have been reporting to the Register. The 5 centers that consistently report treat approximately 90% of the cases in their respective regions. The remaining centers have reported all the patients who were treated during certain time periods, but not for the entire 25-year period. Results - 59% of patients were referred to a sarcoma center untouched, i.e. before any attempt at open biopsy. There was an improvement from 52% during the first 5 years to 70% during the last 5 years. 50% had wide or better margins at surgery. Wide margins are now achieved less often than 20 years ago, in parallel with an increase in the use of radiotherapy. For the centers that consistently report, 97% of surviving patients are followed for more than 4 years. Metastasis-free survival (MFS) increased from 67% to 73% during the 25-year period. Interpretation - The Register is considered to be representative of extremity and trunk wall sarcoma disease in the population of Scandinavia, treated at the reporting centers. There were no clinically significant differences in treatment results at these centers., Funding Agencies|National Advisory Unit on sarcomas in Norway; Swedish Cancer Society

Published
2017
Full Text
View/download PDF

9. The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma

Author

Trovik, Clement, primary, Bauer, Henrik C F, additional, Styring, Emelie, additional, Sundby Hall, Kirsten, additional, Vult Von Steyern, Fredrik, additional, Eriksson, Sigvard, additional, Johansson, Ingela, additional, Sampo, Mika, additional, Laitinen, Minna, additional, Kalén, Anders, additional, Jónsson, Halldór, additional, Jebsen, Nina, additional, Eriksson, Mikael, additional, Tukiainen, Erkki, additional, Wall, Najme, additional, Zaikova, Olga, additional, Sigurðsson, Helgi, additional, Lehtinen, Tuula, additional, Bjerkehagen, Bodil, additional, Skorpil, Mikael, additional, Egil Eide, Geir, additional, Johansson, Elisabeth, additional, and Alvegard, Thor A, additional

Published
2017
Full Text
View/download PDF

10. Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial.

Author

Joensuu, Heikki, primary, Eriksson, Mikael, additional, Sundby Hall, Kirsten, additional, Reichardt, Annette, additional, Ramadori, Giuliano, additional, Hohenberger, Peter, additional, Al-Batran, Salah-Eddin, additional, Schlemmer, Marcus, additional, Bauer, Sebastian, additional, Pink, Daniel, additional, Duyster, Justus, additional, Nilsson, Bengt E., additional, Monge, Odd R, additional, Kallio, Raija, additional, Bono, Petri, additional, Junnila, Jouni, additional, Wardelmann, Eva, additional, Alvegard, Thor, additional, and Reichardt, Peter, additional

Published
2015
Full Text
View/download PDF

11. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol

Author

Serra, Massimo, primary, Pasello, Michela, additional, Manara, Maria, additional, Scotlandi, Katia, additional, Ferrari, Stefano, additional, Bertoni, Franco, additional, Mercuri, Mario, additional, Alvegard, Thor, additional, Picci, Piero, additional, Bacci, Gaetano, additional, and Smeland, Sigbjørn, additional

Published
2006
Full Text
View/download PDF

12. The Scandinavian Sarcoma Group Register.

Author

Bauer, Henrik C.F., Alvegard, Thor A., Berlin, Orjan, Erlanson, Martin, Gustafson, Pelle, Kivioja, Arne, Klepp, Ragnhild, Lehtinen, Tuula, Lindholm, Paula, Moller, Torgil R., Rydholm, Anders, Saeter, Gunnar, Trovik, Clement S., Wahlstrom, Ola, and Wiklund, Tom

Subjects
*OSTEOSARCOMA, *SOFT tissue tumors
Abstract

Provides data of patients with bone or soft tissue sarcoma of the extremities or trunk wall diagnosed between March 1, 1986 and December 31, 1997 in Scandinavia. Participating centers and number of patients reported; Histological type and grade; Treatment of patients with osteosarcoma and Ewing's sarcoma according to Scandinavian Sarcoma Group protocols.

Published
1999
Full Text
View/download PDF

13. Clinical course in synovial sarcoma.

Author

Skytting, Bjorn T., Bauer, Henrik C.F., Perfekt, Roland, Huuhtanen, Riika, Alvegard, Thor A., Berlin, Orjan, Gustafson, Pelle, Klepp, Ragnhild, Lofvenberg, Richard, Saeter, Gunnar, Trovik, Clement S., and Wahlstrom, Ola

Subjects
SYNOVIAL membrane tumors, CANCER treatment, SARCOMA, HEALTH outcome assessment, SURVIVAL analysis (Biometry)
Abstract

Analyzes treatment and outcome in Scandinavian patients with synovial sarcoma in the extremities, diagnosed between 1986 and 1994. Survival rates; Risk of local recurrence; Clinical factors affecting disease metastasis.

Published
1999
Full Text
View/download PDF

14. Chemotherapy in osteosarcoma.

Author

Saeter, Gunnar, Wiebe, Thomas, Wiklund, Tom, Monge, Odd, Wahlqvist, Yngve, Engstrom, Katarina, Forestier, Erik, Holmstrom, Teddy, Stenwig, Anna E., Willen, Helena, Brosio, Otte, Folleras, Gunnar, Alvegard, Thor A., and Strander, Hans

Subjects
OSTEOSARCOMA, DRUG therapy, METHOTREXATE
Abstract

Discusses the development of chemotherapy procedures for use in the treatment of osteosarcoma. Introduction of high doses of methotrexate (MTX); Components of osteosarcoma protocols; Correlation between histologic response and serum levels of MTX.

Published
1999

15. Chemotherapy in soft tissue sarcoma.

Author

Fernberg, Jan-Olof, Wiklund, Tom, Monge, Odd, Hall, Kirsten Sundby, Saeter, Gunnar, Alvegard, Thor A., and Strander, Hans

Subjects
SOFT tissue tumors, DRUG therapy, DOXORUBICIN
Abstract

Discusses the development of chemotherapy procedures for use in the treatment of soft tissue sarcoma. Factors of importance for chemotherapeutic sensitivity for soft tissue sarcomas; Evaluation of agent adjuvant doxorubicin; Analysis of patients undergoing surgery after preoperative chemotherapy.

Published
1999
Full Text
View/download PDF

16. Chemotherapy in Ewing's sarcoma.

Author

Elomaa, Inkeri, Blomqvist, Carl, Saeter, Gunnar, Nilbert, Mef, Monge, Odd R., Wiebe, Thomas, and Alvegard, Thor A.

Subjects
EWING'S sarcoma, DRUG therapy, RADIOTHERAPY
Abstract

Focuses on the development of chemotherapy procedures for use in the treatment of Ewing's sarcoma. Combination of radiotherapy and surgery; Treatment protocols; Response of the tumor to chemotherapy using Huvos' grading system; Causes of improved local therapy.

Published
1999
Full Text
View/download PDF

17. Prognostic factors in soft tissue sarcoma.

Author

Rydholm, Anders, Gustafson, Pelle, Alvegard, Thor A., Saeter, Gunnar, and Blomqvist, C.

Subjects
SOFT tissue tumors, HISTOPATHOLOGY, CHROMOSOME abnormalities
Abstract

Presents the prognostic factors in soft tissue sarcoma (STS). Specific problems in STS; Tumor localization and size; Histopathologic features; Proliferation markers; Chromosome and gene abnormalities; Survival after pulmonary metastasectomy.

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results